Price
No data yet.
Social Signal Score
Analyst Ratings
14 analystsRevenue
$45.69M+10272.08%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Christian Martin Itin
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 752
- Beta
- 2.09
- Country
- GB
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -4.24
Financials
Revenue
$45.69M+10272.1%Net Income
$-39.11MEBITDA
$-33.81MFree Cash Flow
$-25.98MEPS (diluted)
$-0.15Shares Outstanding (diluted)
266.16M+2168.8%Operating Expenses
$69.06MCash & Debt
$201.63MReturn of Capital
$0.00Revenue by Segment (annual)
$75.39MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $75.56M | $-288.20M | $-1.08 |
| 2024 | $10.12M | $-220.66M | $-0.87 |
| 2023 | $1.70M | $-208.38M | $-1.20 |
| 2022 | $6.19M | $-148.84M | $-1.57 |
| 2021 | $1.51M | $-142.10M | $-1.97 |
| 2020 | $1.72M | $-142.09M | $-2.76 |
| 2019 | $2.91M | $-123.85M | $-2.88 |
| 2018 | $1.05M | $-31.11M | $-0.99 |
| 2017 | $1.69M | $-19.73M | $-1.43 |
| 2016 | $1.21M | $-12.55M | $-0.91 |
| 2015 | $94.1K | $-7.46M | $-0.54 |
Valuation
AUTLhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
168+4.69%Social Signal Score
Mentions (5)
- Newszacks.com·21h ago·Positive
All You Need to Know About Autolus Therapeutics (AUTL) Rating Upgrade to Buy Autolus Therapeutics (AUTL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
View source ↗ - Newsglobenewswire.com·1d ago·Positive
…YSLE Trial at the American College of Rheumatology Convergence 2026 LONDON and GAITHERSBURG, Md., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced the online publication of an abstract submitted to the American College of Rheumatology (ACR) Convergence 2026 meeting being held November 6-11, 2026 in Orlando, Flo…
View source ↗ - Newsglobenewswire.com·27d ago·Negative
… the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis LONDON and GAITHERSBURG, Md., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to obecabtagene autoleucel (obe-cel) for the t…
View source ↗ - Newsseekingalpha.com·55d ago·Positive
Autolus Therapeutics plc (AUTL) Q2 2026 Earnings Call Transcript Autolus Therapeutics plc (AUTL) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·56d ago·Neutral
Autolus Therapeutics Q2 Earnings Call Highlights Autolus Therapeutics NASDAQ: AUTL reported second-quarter 2026 net product revenue of $45.7 million from sales of AUCATZYL, up from $26.2 million in the first quarter and $20.9 million a year earlier, as the company expanded treatment-center access and continued its commercial launch in the United States and United Kingdom.
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $-0.20 per share
Typical surprise +6.9% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 11$-0.15 vs $-0.21beat
- Thu, May 14$-0.27 vs $-0.29beat
- Fri, Mar 27$-0.34 vs $-0.26miss
- Wed, Nov 12$-0.30 vs $-0.23miss
- Tue, Aug 12$-0.18 vs $-0.24beat
- Thu, May 8$-0.26 vs $-0.24miss
Estimates and results for AUTL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by AUTL officers and directors.
- Bought
- —
- Sold
- $16k
0 trades
1 trade
- Piccina Cintiasold
99 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in AUTL.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.